Report #2887732

Received Mar 5, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 68 yrs
State: —
Recovered: Unknown
Vaccinated: Feb 15, 2026
Onset: Feb 15, 2026
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	UNK	—

Symptoms (1)

Nausea

Symptom narrative

Intermittent nausea; This non-serious case was reported by a consumer and described the occurrence of nausea in a 68-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (1st dose taken on 23-OCT-2025.). Concurrent medical conditions included polycythemia vera. Concomitant products included hydroxycarbamide (Hydroxyurea). On 15-FEB-2026, the patient received the 2nd dose of Shingrix. On 15-FEB-2026, less than a day after receiving Shingrix, the patient experienced nausea (Verbatim: Intermittent nausea). The outcome of the nausea was unknown. It was unknown if the reporter considered the nausea to be related to Shingrix. It was unknown if the company considered the nausea to be related to Shingrix. Additional Information: GSK receipt date 23-FEB-2026 The patient self-reported the case. The symptoms were not treated. The batch number was not provided and a request for this information has been made.

Current illness

Polycythemia vera

Other medications

HYDROXYUREA